With CAR‑T, one batch equals one patient. There is no finished‑goods inventory and the entire vein‑to‑vein process must be completed in roughly four weeks, including an 11‑day manufacturing cycle once cells arrive at the site. Patient material typically has a viability window of 24 to 72 hours, so delays or missed slots can mean a lost opportunity for treatment or cascading disruptions to other patients’ schedules. In the early commercial phase, Legend Biotech managed a small number of daily runs using whiteboards and spreadsheets, but this quickly became unsustainable as volumes increased and additional sites came online.
At launch, Legend Biotech’s primary goal was to maximize patient access in the face of demand that significantly exceeded supply. In 2022, the network started with two patient runs per day and relied heavily on manual problem‑solving, heroic firefighting, and overtime to protect capacity. As more centers were added and a CDMO partner joined the network, it became clear that:
James Carr, Associate Director of Supply Chain at Legend Biotech’s Raritan site, summarized the pre-Binocs landscape:
We quickly realized that if we wanted to get to the targets we set for ourselves, Excel wasn’t going to be a sustainable approach.
Legend Biotech selected Binocs™ from Bluecrux as the backbone for CAR‑T scheduling across its manufacturing network. Binocs is an AI‑powered planning and scheduling platform designed for life science environments, with specific extensions to support autologous cell and gene therapy operations.
Today, Binocs is used at three Legend Biotech manufacturing sites to manage:
Moving away from fragile, macro‑driven spreadsheets to a single, trusted schedule that covers manufacturing operations, production support, QC, QA reviews, and documentation. Everyone now works from the same real‑time view of constraints, priorities, and patient commitments.
Automating short‑term scheduling based on operator availability and training, equipment capacity, batch priority, and CGT‑specific rules. Binocs generates integrated schedules with a single click and keeps them aligned with execution data through integrations to systems such as SAP for slot management and MES for activity tracking.
Introducing performance dashboards and forward‑looking visibility to support continuous improvement. Legend Biotech uses Binocs analytics to monitor capacity utilization, identify bottlenecks, and balance buffer time against throughput, helping shift the focus from “just keep up” to “improve access and affordability.”
Extending from daily scheduling to mid‑ and long‑term capacity planning so Legend Biotech can confidently plan ramp‑ups, new sites, and CDMO expansion. The same constraint set is applied in tactical and strategic horizons, which supports reliable scale‑up without compromising patient experience.
With Binocs as its scheduling engine, Legend Biotech has been able to:
“With Binocs, we can track and resolve conflicts by process or operation in real time, maximizing our slot utilization,” James explained.
With Phase 1 complete, Legend Biotech is focusing on:
As James Carr outlined at our 2024 Binocs Community Day, “We’ve realized the importance of digitization in the cell and gene therapy industry. Solutions like Binocs are critical to scaling effectively and delivering for our patients.”
Legend Biotech’s commercial journey with its CARVYKTI therapy–and Binocs’ role in helping them achieve success–was given the spotlight in a recent article from Cell & Gene magazine. Check it out here!
And, if you would like to discuss how Binocs™ can support your own CGT manufacturing or QC operations, we are always happy to share lessons learned from the Legend Biotech partnership and other advanced therapy programs.
